BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
1. Delete "and, therefore, to improve patients' safety" from the last sentence of the abstract. Patient safety was not measured in this study.
2. More information of the healthcare system in Switzerland would be beneficial to an international audience. For example, are people registered with one pharmacy or can they collect medications from any pharmacy? 3. Line 25, page 3: "of all patients are involved in an ADE during". Suggest changing "involved in" to "experienced".
4. What's the difference between drug-link error and medication error? If none, consider changing wording as the term medication error is know to most readers.
5. You state that the aim of the study was to investigate the clinical impact of MedRec. The study you designed and conducted investigate the number of discrepancies and their potential in causing harmful ADEs. The aim should be re-worded to better reflect what you have done.
6. Line 31, page 4. Change "A 50% pharmacist dedicated" to 0.5 FTE or something along those lines. 7. Can you described the training events the pharmacist attended? What type of training events? Organised by whom?
8. You write that identified discrepancies were communicated to the physician in charge. How did they communicate? Did you document your findings? Were any of the identified discrepancies intentional but undocumented?
9. Can you please comment on why you chose to adapt the classification of discrepancies? Why not use a the same classification system for example the same classification as Cornish et al used? (unlikely to cause patient discomfort or clinical deterioration, potential to cause moderate discomfort or clinical deterioration, potential to result in severe discomfort or clinical deterioration) 10. I'm interested to know how time was measured and recorded. Was it the pharmacist who recorded how long each step of the process took? Were there reminders to start/stop timing? 11. You state that at least two sources should be used when creating a BPMH and report that the number of sources used in this study ranged from 1-6. For how many patients was only one source used? What attempts wre made to access a second source?
12. Line 51, page 10 "indeed, 96%..." appears to be out of context. Consider moving or deleting the sentence.
13. The last sentence in the conclusion needs to be re-worded. You can't say, based on the results of this study, that MedRec is an important strategy to improve patient safety. You could write that MedRec is an effective strategy in detecting unintentional discrepancies that have the potential to cause harmful ADEs.
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GENERAL COMMENTS
This paper describes a well designed study observing the prevalence of medication discrepancies revealed by medication reconciliation at hospital admission. The results are local to Switzerland, but will contribute to the body of evidence that medication reconciliation is important anywhere in the world -be it developed healthcare systems or countries with less developed healthcare systems.
I have only a few minor suggestions of edits and further information (if available), to further tighten this already well designed (as far as medication reconciliation type observation study design is concerned).
Methods
Page 4 of 20 line 31. I understand what you mean by 50% pharmacist -as in a pharmacist spending 50% of their working time on the medication reconciliation program. This just doesn't read as well when shortened to "50% pharmacist" -so perhaps editing this to make it read a bit better. 
VERSION 1 -AUTHOR RESPONSE

Reviewer #1
1) It would be better to include the criteria that the expert panel use to classify the clinical relevance of medication discrepancy (significant vs serious).
Thank you for your suggestion. According to this comment, we added the criteria used to classify the clinical relevance of medication discrepancies as follow: "…medication discrepancies were classified into the following severity categories: non-relevant (i.e. unlikely to cause patient discomfort or clinical deterioration), relevant as significant (i.e. with the potential to cause moderate discomfort or clinical deterioration) or relevant as serious (i.e. with the potential to cause severe discomfort or clinical deterioration) and non-classifiable (i.e. insufficient information available to classify)" This information is now provided in page 5 under "Data collection". We completely agree and accordantly we provide now a new section entitled "Strengths and weaknesses of the study" under the Discussion section addressing this limitation: "An important limitation of the present study is that it did not assess patient's relevant outcomes as mortality, incidence of ADEs, lengths of stay, readmissions, and subsequent visits to the emergency department. Others studies investigated the association between MedRec and patients' outcomes but with inconclusive results calling for further research [43, 44] ." (page 13)
Reviewer #2
2) Delete "and, therefore, to improve patients' safety" from the last sentence of the abstract. Patient safety was not measured in this study.
We followed the reviewer's suggestion and we delete this information.
3) In order to make this point clearer and to facilitate the reading we added the reference number 20 on page 3 (N Engl J Med 2015;373:2193-97), which describes in detail the healthcare system in
Switzerland. An exhaustive description of the Swiss health care system would be very difficult to provide in the limited space available in the manuscript. In fact, the health system in Switzerland is quite complex including 26 cantons, whit they own peculiarities.
4)
Line 25, page 3: "of all patients are involved in an ADE during". Suggest changing "involved in" to "experienced".
We followed the reviewer's suggestion.
5) What's the difference between drug-link error and medication error? If none, consider changing wording as the term medication error is know to most readers.
We agree and we changed consequently. Throughout the manuscript, we have now used only "medication error". We completely agree and we thank you for this relevant comment. We reformulated now the sentence on page 4 as follows: "The aim of the study was to investigate the number and types of medication discrepancies between a standard physician-acquired medication history and a pharmacist-acquired BPMH, and by evaluating their potential clinical relevance to cause an ADE".
7) Line 31, page 4. Change "A 50% pharmacist dedicated" to 0.5 FTE or something along those lines.
Yes, we did.
8) Can you described the training events the pharmacist attended? What type of training events?
Organised by whom?
Thank you for your suggestion. In order to make this point clearer, we modified the manuscript in the Methods section (page 4) as follows: "The pharmacist was trained in MedRec during two fullday workshops organized by the Patient Safety Foundation Switzerland (https://www.patientensicherheit.ch). The workshops included presentations by experts, discussion groups and role-playing exercises in taking a BPMH."
9) You write that identified discrepancies were communicated to the physician in charge. How did they communicate? Did you document your findings? Were any of the identified discrepancies intentional but undocumented?
We agree that we provided insufficient information regarding the communication process.
Accordingly to your comment, we added this information in the Methods section (page 4) as follows:
"The medication discrepancies were communicated to the physician in charge using an electronic message system." "The medication list obtained by the pharmacist was documented in the EMR system, which was adapted to integrate the new pre-admission list in the list previously documented by the doctor. The medications discrepancies were automatically visible on this page."
To the best of our knowledge, no intentional discrepancies were undocumented.
10)
Can you please comment on why you chose to adapt the classification of discrepancies? Why not use a the same classification system for example the same classification as Cornish et al used? (unlikely to cause patient discomfort or clinical deterioration, potential to cause moderate discomfort or clinical deterioration, potential to result in severe discomfort or clinical deterioration).
Thank you for your comment. Indeed, we used the same classification system as proposed by Cornish et al., but we recognize that this was not clearly formulated. According to this comment, we revised the manuscript and we added the criteria to classify the clinical relevance of medication discrepancies as follow: "In agreement to a method described elsewhere [23] , medication discrepancies were classified according to the potential to cause an ADE into the following severity categories: nonrelevant (i.e. unlikely to cause patient discomfort or clinical deterioration), relevant as significant (i.e.
with the potential to cause moderate discomfort or clinical deterioration) or relevant as serious (i.e. with the potential to cause severe discomfort or clinical deterioration) and nonclassifiable (i.e. insufficient information available to classify)." (page 5) and we adapted the references accordingly. 
12)
You state that at least two sources should be used when creating a BPMH and report that the number of sources used in this study ranged from 1-6. For how many patients was only one source used? What attempts were made to access a second source?
In agreement with this comment, we edited the following new paragraph in the Methods section: "Other sources of information were the medication list provided by the community pharmacy, the primary care physician, the nursing home and home care. Patients or their relatives were also requested to bring their drug packages to the hospital. Information was collected by telephone or sent by fax or email". We also added the following new paragraph in the Results section: "For three patients we used only one source of information for the BPMH. Two of them were residents in elderly homes and it was not possible to perform the interview with the patients and/or caregivers, so only the therapy plan provided by the nursing home was used. For the third patient, only the structured interview was performed.".
13)
Line 51, page 10 "indeed, 96%..." appears to be out of context. Consider moving or deleting the sentence.
14)
The last sentence in the conclusion needs to be re-worded. You can't say, based on the results
of this study, that MedRec is an important strategy to improve patient safety. You could write that
MedRec is an effective strategy in detecting unintentional discrepancies that have the potential to cause harmful ADEs.
We completely agree and we thank you for this important comment and suggestion. We reformulated the sentence accordingly as follows: "The introduction of a standardized and systematic MedRec process including a BPMH is an effective strategy in detecting unintentional medication discrepancies that have the potential to cause clinically relevant ADEs." You are absolutely right. This point was observed also by Reviewer #2. In order to make this point clearer we edited the sentence as follow: "A pharmacist (0.5 FTE) was dedicated to the program for two years".
2)
Page 4 of . Did the study pharmacist exclude patients who were not on any regular prescribed medications? Please include an exclusion criteria to clarify. We thank you for raising this point. For this study we excluded only terminally ill (life expectancy of few days) patients and this single exclusion criterion is now provided in the Methods section (page 4).
3)
Page 5 
